当前位置: X-MOL 学术Drug. Discov. Today › 论文详情
Our official English website, www.x-mol.net, welcomes your feedback! (Note: you will need to create a separate account there.)
Haspin: a promising target for the design of inhibitors as potent anticancer drugs
Drug Discovery Today ( IF 6.5 ) Pub Date : 2017-10-13 , DOI: 10.1016/j.drudis.2017.10.005
Nathalie Gisèle Amoussou , André Bigot , Christos Roussakis , Jean-Michel H. Robert

Protein kinases constitute a large group of enzymes in eukaryotes and have an important role in many cellular processes. Several of these proteins are active kinases, such as haploid germ cell-specific nuclear protein kinase (Haspin), an atypical eukaryotic protein kinase that lacks sequence similarity with other eukaryotic protein kinases. Haspin is a serine/threonine kinase that associates with chromosome and phosphorylates threonine 3 of histone 3 during mitosis. Haspin overexpression or deletion results in defective mitosis. It has been shown that Haspin inhibitors have potent anti-tumoral effects. Given that the only Haspin substrate is threonine 3 of histone 3, inhibition of Haspin might have fewer adverse effects compared with other anticancer agents. Here, we highlight the chemical structures and actions of currently known Haspin inhibitors.



中文翻译:

Haspin:将抑制剂设计为有效抗癌药物的有希望的目标

蛋白激酶构成了真核生物中的一大类酶,并且在许多细胞过程中都起着重要作用。这些蛋白中的几种是活性激酶,例如单倍体生殖细胞特异性核蛋白激酶(Haspin),这是一种非典型的真核蛋白激酶,与其他真核蛋白激酶缺乏序列相似性。Haspin是一种丝氨酸/苏氨酸激酶,在有丝分裂过程中与染色体缔合并使组蛋白3的苏氨酸3磷酸化。Haspin过表达或缺失会导致有丝分裂不良。已经表明,Haspin抑制剂具有有效的抗肿瘤作用。鉴于唯一的Haspin底物是组蛋白3的苏氨酸3,与其他抗癌药相比,抑制Haspin的不良反应可能更少。这里,

更新日期:2017-10-13
down
wechat
bug